



## Earnings Presentation – 4<sup>th</sup> Quarter, 2018

# Disclaimer Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this presentation other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this presentation. These factors include, among other things: general economic and business conditions, both nationally and in the regions in which we operate; the impact of health reform initiatives, including the Affordable Care Act, and the potential for the Affordable Care Act to be repealed or found unconstitutional or for additional changes to the law, its implementation or its interpretation (including through executive orders and court challenges); the extent to which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through regulation or otherwise; the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process; risks associated with our substantial indebtedness, leverage and debt service obligations, and the fact that a substantial portion of our indebtedness will mature and become due in the near future, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness; demographic changes; changes in, or the failure to comply with, federal, state or local laws or governmental regulations affecting our business; potential adverse impact of known and unknown government investigations, audits, and federal and state false claims act litigation and other legal proceedings; our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers; changes in, or the failure to comply with, contract terms with payors and changes in reimbursement rates paid by federal or state healthcare programs or commercial payors; any potential additional impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies; the effects related to the continued implementation of the sequestration spending reductions and the potential for future deficit reduction legislation; increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles; the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing; increases in wages as a result of inflation or competition for highly technical positions and rising supply and drug costs due to market pressure from pharmaceutical companies and new product releases; liabilities and other claims asserted against us, including self-insured malpractice claims; competition; our ability to attract and retain, at reasonable employment costs, qualified personnel, key management, physicians, nurses and other healthcare workers; trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals; changes in medical or other technology; changes in U.S. generally accepted accounting principles; the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures; our ability to successfully make acquisitions or complete divestitures, including the disposition of hospitals and non-hospital businesses pursuant to our portfolio rationalization and deleveraging strategy, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures; the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities; our ability to successfully integrate any acquired hospitals, or to recognize expected synergies from acquisitions; the impact of seasonal severe weather conditions, including the timing and amount of insurance recoveries in relation to severe weather events; our ability to obtain adequate levels of general and professional liability insurance; timeliness of reimbursement payments received under government programs; effects related to outbreaks of infectious diseases; the impact of prior or potential future cyber-attacks or security breaches; any failure to comply with the terms of the Corporate Integrity Agreement; the concentration of our revenue in a small number of states; our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives; changes in interpretations, assumptions and expectations regarding the Tax Act; and the other risk factors set forth in our other public filings with the Securities and Exchange Commission.

The consolidated operating results for the three months and year ended December 31, 2018, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the projections for calendar year 2019 set forth in this presentation are given as of the date hereof based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

# Community Health Systems

- Wayne T. Smith  
Chairman and CEO
- Tim L. Hingtgen  
President and COO
- Thomas J. Aaron  
Executive Vice President and CFO
- Lynn T. Simon  
President and CMO

Earnings Presentation – 4<sup>th</sup> Quarter, 2018

# Income Summary

(Amounts in millions, except margin and EPS)

	Three Months Ended December 31,			Year Ended December 31,		
	2018	2017	Change	2018	2017	Change
Net Operating Revenues	\$ 3,453	\$ 3,650	-5.5%	\$ 14,155	\$ 15,945	-11.2%
Adjusted EBITDA <sup>(1)</sup>	\$ 419	\$ 409	2.4%	\$ 1,642	\$ 1,703	-3.6%
Adjusted EBITDA Margin <sup>(1)</sup>	12.1%	11.2%	90 BPS	11.6%	10.7%	90 BPS
EPS from Continuing Operations, Excluding Adjustments <sup>(2)</sup>	\$ (0.42)	\$ (0.25)	-68.0%	\$ (1.94)	\$ (1.20)	-61.7%
Shares Outstanding (Weighted and Fully Diluted)	113	112		113	112	

(1) See the Unaudited Supplemental Information contained in this presentation for a definition of Adjusted EBITDA and a reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from our consolidated financial statements for the three months and years ended December 31, 2018 and 2017 (slides 18 and 19).

(2) See reconciliation of diluted EPS excluding adjustments on slide 5.

Note: The 2017 results exclude the change in estimate for contractual allowances and provision for bad debts recorded during the three months ended December 31, 2017.

# Diluted EPS – Excluding Adjustments

	Three Months Ended December 31,		Year Ended December 31,	
	2018	2017	2018	2017
Net loss, as reported	\$ (2.91)	\$ (17.98)	\$ (6.99)	\$ (22.00)
Adjustments:				
Discontinued operations	-	0.03	-	0.11
Loss (gain) from early extinguishment of debt	0.02	0.03	(0.20)	0.23
Impairment and (gain) loss on sale of businesses, net	2.34	13.94	4.66	16.84
Expense (income) from government and other legal settlements and related costs	0.01	-	0.07	(0.18)
Expense from settlement and fair value adjustments and legal expenses related to cases covered by the CVR	-	-	0.09	0.04
Expense related to employee termination benefits and other restructuring charges	0.02	0.06	0.13	0.08
Change in estimate for contractual allowances and provision for bad debts	-	3.38	-	3.38
Expense related to change in corporate income tax rate	-	0.29	-	0.29
Tax effect of non-deductible portion of HMA legal settlement	0.10	-	0.30	-
Loss from continuing operations, excluding adjustments	\$ (0.42)	\$ (0.25)	\$ (1.94)	\$ (1.20)

*(Total per share amounts may not add due to rounding)*

# 4Q 2018 Highlights

	4Q 2018 compared to 4Q 2017		FY 2018 compared to FY 2017	
	Consolidated	Same Store	Consolidated	Same Store
Net Operating Revenue	-5.5%	1.9%	-11.2%	2.8%
Net Revenue per AA		1.8% *		3.2% *
Admissions	-9.7%	-0.5%	-15.0%	-1.3%
Adjusted Admissions	-9.8%	0.1%	-15.3%	-0.4%
Surgeries	-6.3%	0.9%	-13.2%	-0.1%
ER Visits	-12.4%	-3.2%	-16.0%	-1.4%

\* Volatility in the stock and bond markets during the fourth quarter of 2018 resulted in declines that reduced the value of investments held in employee deferred compensation plans, resulting in lower other revenue and a corresponding reduction in benefit expense. On a net basis, this had no EBITDA impact. Excluding this item, fourth quarter and full year 2018 Net Revenue per AA would have been up 2.9% and 3.5%, respectively.

# 2018 Quarterly Same Store Highlights

Recast with 112 hospitals in each period.

(\$ in millions)

	1Q18	2Q18	3Q18	4Q18	FY18
Net Operating Revenue	\$3,354	\$3,288	\$3,289	\$3,400	\$13,331
Net Operating Revenue Growth	2.0%	3.6%	3.8%	1.9%	2.8%
Net Revenue per AA	3.9%	3.3%	3.8%	1.8% *	3.2% *
Admissions	-2.4%	-1.4%	-1.1%	-0.5%	-1.3%
Adjusted Admissions	-1.9%	0.3%	0.0%	0.1%	-0.4%
Surgeries	-2.2%	0.4%	0.7%	0.9%	-0.1%
ER Visits	0.6%	-1.8%	-1.3%	-3.2%	-1.4%

\* See note on Slide 6.

Note: The 112 hospitals above includes the 2 Mary Black Health System hospitals in South Carolina that were divested with an effective date of January 1, 2019.

# 4Q 2018 Financial and Operating Results

## Year-Over-Year Change as a Percentage of Same Store Net Operating Revenues

### Same Store

---

- **Salaries and benefits** **-120BPS**
    - Driven by improved FTE management.

---

  - **Supplies expense** **+10BPS**
    - Driven by higher implant expense offset by lower commodity spend.

---





  - **Other operating expenses** **+80BPS**
    - Driven by higher medical specialist fees, purchased services, information systems expense, and insurance costs.

---

  - **Electronic health records incentive reimbursement** – lower than the same period in the prior year by \$0.4 million.
-



# Payor Mix (Consolidated)



- Payor mix is presented as a percent of net revenue after the provision for uncollectible revenue (for 2017, provision for bad debt).
- Total consolidated uncompensated care as a percent of adjusted net revenue (net revenue before the provision for uncollectible revenue + charity care + administrative self pay discount) for the three months ended December 31, 2018, was 31.1% compared to 30.4% for the same period in 2017.
- 2017 revenue used in calculation excludes the change in estimate for contractual allowances and provision for bad debts recorded during the three months ended December 31, 2017.


### Key

- Managed Care & Other
- Medicaid
- Medicare
- Self-Pay

# Cash Flow & Capital Expenditures

## Cash Flows from Operations


(\$ in millions)



\* See slide 11 for analysis of operating cash flow.

## Capital Expenditures

(\$ in millions)



	2014	2015	2016	2017	2018
CapEx % of Net Revenue (includes replacement hospitals)	4.6%	4.9%	4.0%	3.5%	3.7%
Replacement Hospitals % of Net Revenue	0.6%	0.6%	0.1%	0.0%	0.0%

# Analysis of Operating Cash Flow

(Amounts in millions)	Three Months Ended December 31,		Year Ended December 31,	
	2018	2017	2018	2017
Cash flows from operations, as reported	\$ (165)	\$ 156	274	773
Adjustments:				
Shareholder derivative settlement received 1Q 2017	-	-	-	(40)
HMA legal settlement paid in 4Q 2018	266	-	266	-
CVR legal costs/divestiture transaction costs	-	-	3	2
Government settlement and legal costs	3	-	6	1
SERP distributions to retired executives	8	29	23	41
Severance and early retirement paid out	-	-	3	-
Non-recurring EHR incentive cash received	-	(8)	-	(40)
	<u>\$ 112</u>	<u>\$ 177</u>	<u>\$ 575</u>	<u>\$ 737</u>


# Balance Sheet Data

(\$ in millions)

	December 31, 2018	December 31, 2017
<b>Working Capital</b>	\$ 1,157	\$ 1,712
<b>Total Assets</b>	\$ 15,859	\$ 17,450
<b>Long Term Debt</b>	\$ 13,392	\$ 13,880
<b>Stockholders' Deficit</b>	\$ (1,535)	\$ (767)

- At December 31, 2018, approximately 94% of our debt was fixed, including swaps.
- Net debt (long-term debt, plus current maturities of long-term debt, less cash and cash equivalents) has been reduced by \$1.6 billion since December 31, 2016.
- Days revenue outstanding for same-store hospitals, adjusted for the impact of receivables for state Medicaid supplemental payment programs, was 58 days at December 31, 2018, and 56 days at December 31, 2017.

# Debt Maturity as of December 31, 2018



■ 2019 (Nov) Senior Unsecured Notes - \$155	■ 2020 (July) Senior Unsecured Notes - \$121
■ 2021 (Jan) TLH - \$1,622	■ 2021 (Aug) Senior Secured Notes - \$1,000
■ 2022 (Feb) Senior Unsecured Notes - \$2,632	■ 2023 (Mar) Senior Secured Notes - \$3,100
■ 2023 (Apr) ABL Facility - \$698	■ 2023 (June) Junior-Priority Notes - \$1,770
■ 2024 (Jan) Senior Secured Notes - \$1,033	■ 2024 (June) Junior-Priority Notes - \$1,355

Allowing for greater investments in stronger markets as well as debt reduction.

## Transactions Completed in 2017

---

- Completed the sale of 30 hospitals
  - Annualized revenue: ~\$3.4 billion, with mid-single digit EBITDA margins
  - Gross proceeds, excluding working capital: ~\$1.7 billion

## 2018 and 2019 Divestiture Plan

---

- Total contemplated divestitures accounted for at least \$2.0 billion of 2017 annual net revenue, with mid-single digit EBITDA margins
- Total estimated gross proceeds, excluding working capital of ~\$1.3 billion
- Expect the remainder of these divestitures to close during 2019

## Transactions Completed in 2018

---

- Completed the sale of 13 hospitals (includes 2 SC hospitals with effective date of 1/1/2019)
  - 2017 annual revenue: ~\$1.1 billion, with low-single digit EBITDA margins
  - Gross proceeds, excluding working capital: ~\$400 million

## Hospital Closures in 2018

---

- Closed 3 hospitals

## Transactions Underway in 2019

---

- Completed the sale of 1 hospital in NJ
- 4 hospitals under definitive agreement in SC

# 2019 Guidance as of February 20, 2019

	2019 Projection Range
• Net operating revenues (in millions)	\$12,800 to \$13,100
• Adjusted EBITDA (in millions)	\$1,625 to \$1,725
• Depreciation and amortization as a percentage of net operating revenues	4.9%
• Interest expense as a percentage of net operating revenues	7.8%
• Loss from continuing operations per share – diluted	\$(1.60) to \$(1.25)
• Weighted-average diluted share (in millions)	114.0 to 114.5
• Net cash provided by operating activities (in millions)	\$600 to \$700
• Capital expenditures (in millions)	\$475 to \$575
• Same-store adjusted admissions	0.0% to 1.0%
• HITECH Incentives (in millions)	\$0

The 2019 projections include the impact of completed and announced divestitures expected to close in 2019.

Our comprehensive 2019 guidance has been provided on pages 17 and 18 on Form 8-K dated February 20, 2019 and includes important assumptions and exclusions.

Our Strategic Imperatives are the most highly-prioritized, high-impact areas of focus for our organization.





## APPENDIX: Other Financial Information

# Unaudited Supplemental Information

EBITDA is a non-GAAP financial measure which consists of net loss attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude the effect of discontinued operations, loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of investments in unconsolidated affiliates, expense incurred related to the spin-off of QHC, expense incurred related to the sale of a majority ownership interest in the Company's home care division, expense (income) related to government and other legal settlements and related costs, expense related to employee termination benefits and other restructuring charges, expense (income) from settlement and fair value adjustments on the CVR agreement liability related to the HMA legal proceedings and related legal expenses, and the overall impact of the change in estimate related to net patient revenue recorded in the fourth quarter of 2017 resulting from the increase in contractual allowances and the provision for bad debts. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests and clarifies for investors the Company's portion of EBITDA generated by continuing operations. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company's hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company's executive management team and is one of the primary targets used to determine short-term cash incentive compensation. In addition, management utilizes Adjusted EBITDA in assessing the Company's consolidated results of operations and operational performance and in comparing the Company's results of operations between periods. The Company believes it is useful to provide investors and other users of the Company's financial statements this performance measure to align with how management assesses the Company's results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company's senior secured credit facility, which is a key component in the determination of the Company's compliance with some of the covenants under the Company's senior secured credit facility (including the Company's ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the senior secured credit facility (although Adjusted EBITDA does not include all of the adjustments described in the senior secured credit facility).

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

# Unaudited Supplemental Information

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):

	Three Months Ended December 31,		Year Ended December 31,	
	2018	2017	2018	2017
Net loss attributable to Community Health Systems, Inc. stockholders	\$ (328)	\$ (2,013)	\$ (788)	\$ (2,459)
Adjustments:				
Benefit from income taxes	(70)	(375)	(11)	(449)
Depreciation and amortization	169	196	700	861
Net income attributable to noncontrolling interests	29	6	84	63
Loss from discontinued operations	-	3	-	12
Interest expense, net	257	225	976	931
Loss (gain) from early extinguishment of debt	1	5	(31)	40
Impairment and (gain) loss on sale of businesses, net	354	1,760	668	2,123
Change in estimate for contractual allowances and provision for bad debts	-	591	-	591
Expense (income) from government and other legal settlements and related costs	2	1	11	(31)
Expense from settlement and fair value adjustments and legal expenses related to cases covered by the CVR	1	-	13	6
Expense related to the sale of a majority interest in home care division	-	-	-	1
Expense related to employee termination benefits and other restructuring charges	4	10	20	14
Adjusted EBITDA	\$ 419	\$ 409	\$ 1,642	\$ 1,703